key: cord-0952535-w4pq0ona
authors: Gupta, Gaurav; S., Roshan; Singh, Yogendra; Thangavelu, Lakshmi; Singh, Sachin Kumar; Dureja, Harish; Chellappan, Dinesh Kumar; Dua, Kamal
title: Emerging cases of mucormycosis under COVID‐19 pandemic in India: Misuse of antibiotics
date: 2021-07-29
journal: Drug Dev Res
DOI: 10.1002/ddr.21862
sha: 3464e72d8a48a4a3b77af0243a39912eea921ef1
doc_id: 952535
cord_uid: w4pq0ona

COVID‐19's second wave had a significant impact on India, on May 7, 2021, the largest daily recorded case count was a little more than 4 million, and it has since fallen. Although the number of new cases reported has dropped, during the third week of May 2021, India accounted for about 45% of new cases identified globally and around 34% of deaths. As India maintains its present level of stability, a new urgent threat has emerged in the form of coronavirus‐associated mucormycosis. Mucormycosis, an acute and deadly fungal infection caused by Mucorales‐related fungal species, is a fungal emergency with a particularly aggressive propensity for contiguous spread, associated with a poor prognosis if not properly and immediately identified, and treated. Mucormycosis, sometimes referred to as the “black fungus,” has increased more rapidly in India during the second wave of COVID‐19 than during the first wave, with at least 14,872 cases as of May 28, 2021. Uncontrolled diabetic mellitus (DM) and other immunosuppressive diseases such as neutropenia and corticosteroid treatment have traditionally been identified as risk factors for mucormycosis. Therefore, the use of glucocorticoids or high doses of glucocorticoids in mild COVID‐19 cases (without hypoxemia) should be avoided. In addition, drugs that target the immune pathway, such as tocilizumab, are not recommended without clear benefits.

urgent threat has emerged in the form of coronavirus-associated mucormycosis.

Mucormycosis, an acute and deadly fungal infection caused by Mucorales-related fungal species, is a fungal emergency with a particularly aggressive propensity for contiguous spread, associated with a poor prognosis if not properly and immediately identified, and treated. Mucormycosis, sometimes referred to as the "black fungus," has increased more rapidly in India during the second wave of COVID-19 than during the first wave, with at least 14,872 cases as of May 28, 2021. Uncontrolled diabetic mellitus (DM) and other immunosuppressive diseases such as neutropenia and corticosteroid treatment have traditionally been identified as risk factors for mucormycosis. Therefore, the use of glucocorticoids or high doses of glucocorticoids in mild COVID-19 cases (without hypoxemia) should be avoided. In addition, drugs that target the immune pathway, such as tocilizumab, are not recommended without clear benefits. mucormycosis, steroids In December 2019, the first case of SARS-CoV-2 (COVID-19) coronavirus disease was identified in Wuhan, China. The disease spread rapidly and was announced as a Public Health Emergency of International Importance on 30 January 2020. On March 11, 2020, the World Health Organization declared it a pandemic. COVID-19, which is caused by the SARS-CoV-2 virus, has been linked to a variety of opportunistic bacterial and fungal diseases (Kubin et al., 2021) .

Both Aspergillosis and Candida have been identified as the primary fungal infections associated with co-infection in COVID-19 patients (Song et al., 2020) . Recently, many instances of mucormycosis in persons living with COVID-19 have been documented globally, most notably in India. COVID-19 associated individuals are prone to serious opportunistic infections due to related comorbidities including COPD and diabetes and immunosuppressed conditions like ventilation, corticosteroid therapy, and ICU stay. As India continues to be infected with around 350,000 new infections every day, the second wave of COVID-19 is shocking, leading to a massive increase in the number of cases requiring strong medication. The disease rate is 0.14 cases per 1000 people, which is 80 times the prevalence rate. Infection with COVID-19 is linked to a fungal infection. Mucormycosis, an acute and deadly fungal infection caused by Mucorales-related fungal species, is a fungal emergency with a particularly aggressive propensity for contiguous spread, associated with a poor prognosis if not properly and immediately identified and treated. Uncontrolled diabetic mellitus (DM) and other immunosuppressive diseases such as neutropenia and corticosteroid treatment have traditionally been identified as risk factors for mucormycosis. Inhalation of spores and/or seeding onto the airways or any susceptible epithelium required for the spread of mucormycosis; using host conditions such as hyperglycemia, ketoacidosis, iron overload, and neutropenia to germinate into angioinvasive hyphae that cause endothelium damage; resulting in local hemorrhaging, thrombosis, and necrosis, as well as eventual spread to numerous organs (Ahmadikia et al., 2021; Cornely et al., 2019; Salehi et al., 2020) .

Although rare, the infection has been around for decades, but it only affects people whose health is compromised by the use of steroids and whose immune system is significantly weakened. Increased cases of mucormycosis in COVID-19 patients are prevalent, primarily due to increased use of steroids such as dexamethasone, especially among diabetics. Not everyone is susceptible to black fungus, but unchecked and (Garg et al., 2021; Saldanha et al., 2021) . In severe COVID-19 cases, the total number of T cells and lymphocytes decreases and has been linked to the most negative outcomes. T cells specific for Mucorales, like CD4 + and CD8 +, produce cytokines such as IFN-γ and IL-4, IL-10, IL-17, and fungal filaments that cause damage. According to Sharma et al., such unique T cells are only present in patients with invasive mycosis, and that they may be useful surrogate diagnostic markers for invasive mycosis. Lymphopenia can raise the chance of transmitting invasive mucormycosis, although an increase in lymphocyte count can be beneficial to the adaptive immune system and induce T cell development specific for Mucorales, which can aid in the control of the invasive infection (Sarkar et al., 2021) .

There are many reports showing changes in cell-mediated immunity involving phagocytosis, chemotaxis, and cytokine secretion in diabetic patients. Diabetes has been associated with changes in the components of the innate immune system. Diabetics have lower natural killer cell function and more pro-inflammatory M1 macrophages are present. In addition, T cell activity is distorted (Chowdhury & Barooah, 2020; Dyer, 2021) . The severity of the patient's illness is due to the host's reaction as well as the viral infection. Blood sugar levels that are too high can also inhibit antiviral responses. About COVID-19, the progression of severe disease is explained by a long-term hyperinflammatory condition and a delayed IFN-γ response with decreased CD4 and CD8 cell numbers.

Irrespective of endothelial cell activity, in diabetic patients, the initial delay in IFN-γ response, together with the hyperinflammatory response, can intensify the "cytokine storm" and make COVID-19 more serious . Endothelial dysfunction is associated with elevated endothelial inflammation, vascular lesions, and vasoconstriction. Diabetics have an increased risk of the endothelium in some organs. Vasoconstriction-induced tissue edema, organ ischemia, and procoagulant states may result from changes in vascular tone. Finally, the dysregulated immune cell population and activity observed in diabetics play an important role in exacerbating severity (Bair et al., 2021) . The Indian subcontinent case series reported six cases of rhino-orbital-encephalomycosis after COVID-19 infection.

The average time from the COVID-19 diagnosis to the onset of zygomycosis symptoms was 15.6 ± 9.6 days. Hyperglycemia control, early treatment with liposomal amphotericin B, and surgery are all necessary components of effective mucormycosis management (Sen, Lahane, et al., 2021) . The development of mucormycosis may be due to the use of glucocorticoids, suggesting the need for their wise use.

Therefore, the use of glucocorticoids or high doses of glucocorticoids in mild COVID-19 cases (without hypoxemia) should be avoided. In addition, drugs that target the immune pathway, such as tocilizumab, are not recommended without clear benefits.

In conclusion, although the complexity of COVID-19 necessitates that doctors treating patients make choices about a range of treatments, basic recommendations for the use and avoidance of specific therapies should guarantee that evidence-based, qualitycontrolled interventions are reasonably consistent. Self-medication and interventions might be strongly prohibited. A set of minimum criteria for all the organizations that care for these individuals may be created.

The authors declare no conflict of interest.

Data sharing, not available-no new data generated ORCID Gaurav Gupta https://orcid.org/0000-0001-7941-0229

The doubleedged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis

COVID-19 lockdowns show reduced pollution on snow and ice in the Indus River Basin

Tea bioactive modulate innate immunity: In perception to COVID-19 pandemic

Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium

Covid-19: India sees record deaths as "black fungus" spreads fear

Evaluation of seven commercial RT-PCR kits for COVID-19 testing in pooled clinical specimens

Differential mortality in COVID-19 patients from India and western countries. Diabetes and Metabolic Syndrome

Characterization of bacterial and fungal infections in hospitalized patients with coronavirus disease 2019 and factors associated with health care-associated infections

Fungal infections of Oral cavity: Diagnosis, management, and association with COVID-19

COVID-19 triggering mucormycosis in a susceptible patient: A new phenomenon in the developing world?

Title of the article: Paranasal Mucormycosis in COVID-19 patient

Opportunistic fungal infections in the epidemic area of COVID-19: A clinical and diagnostic perspective from Iran

COVID-19 and orbital mucormycosis

COVID-19 and eye: A review of ophthalmic manifestations of COVID-19

Mucor in a viral land: A tale of two pathogens

Spice-infused Palmyra palm syrup improved cell-mediated immunity in Wistar albino rats

Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China

Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics